---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-045761"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:52:20.930516+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023

## Summary
- Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).
- Gross margin improved to 45.6% from 44.3%; adjusted EBITDA loss narrowed to $0.8M from $2.3M.
- Cash balance $0.5M at year-end vs $1.3M; net proceeds of $0.9M from Streeterville financing in Q3 2024.
- Acquired Elevated Softgels in Q2 2024; launched +PlusHLTH brand and Lunar Fox plant-based line.
- Retained Maxim Group as non-exclusive financial advisor; evaluating M&A opportunities.

## SEC filing metadata
- accession: 0000950170-25-045761
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017025045761/0000950170-25-045761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017025045761/cvsi-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-045761
- JSON: https://secwatch.observer/filing/0000950170-25-045761.json
- Plain text: https://secwatch.observer/filing/0000950170-25-045761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.